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Abstract The inXammation process in psoriatic skin is
characterized by inXux of leukocytes, hyperproliferation
and aberrant diVerentiation of keratinocytes regulated via
cytokines. Dipeptidyl-peptidase IV (DPPIV) is known to be
upregulated on keratinocytes in the psoriatic lesion. The
objective was to gain insight into dynamics of DPPIV
expression and enzyme activity together with keratinocyte
proliferation and diVerentiation markers during develop-
ment of a psoriatic lesion, in order to investigate coherence
in mechanisms behind the upregulation of DPPIV in psori-
atic skin. The expression of DPPIV, Ki-67 antigen and ker-
atin-16 (K16) was studied in the dynamic margin zone of
the psoriatic lesion, examining skin sections of the clini-
cally uninvolved skin, the early lesion and the chronic
lesion of psoriatic patients compared to healthy volunteers
using immunohistochemical and enzymehistochemical
staining methods. DPPIV-expression and enzyme activity,
Ki-67 antigen and K16 are signiWcantly upregulated in the
centre and inner margin of the lesion compared to clinically
uninvolved skin and the healthy volunteers skin. Mutually
between the centre and inner margin, this upregulation did
not diVer signiWcantly. The clinical symptomless skin
proved to have signiWcantly elevated DPPIV enzyme activ-
ity compared to the skin of healthy volunteers. We demon-
strate that DPPIV is expressed and enzymatically active
well before the development of an overt psoriatic lesion.
The abnormal DPPIV distribution in psoriatic skin does not
coincide with known markers of aberrant growth and diVer-
entiation of keratinocytes, which makes DPPIV (expression
and enzyme activity) a marker standing on its own.
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Introduction
Psoriasis is considered to be an organ-speciWc autoimmune
disease, caused by a combination of genetic and environ-
mental factors and is triggered and maintained by an acti-
vated cellular immune system. Its pathology is mainly
characterized by cutaneous inXammatory inXux of leuko-
cytes and hyperproliferation and aberrant diVerentiation of
keratinocytes. Within the psoriatic lesion, there is a mutual
interaction between these keratinocytes and mononuclear
leukocytes by means of a third involved party, the cyto-
kines [5, 11]. The chemical modiWcation of cytokines and
hence the modiWcation of their physiological function is of
major importance to understand their actual role in the
pathophysiology of the psoriatic process.
Dipeptidyl peptidase IV (CD26) is a 110-kDa mem-
brane-anchored glycoprotein with a variety of functions [1,
4]. In general, it is widely distributed throughout the human
body and varies in density and form between various
organs and cell types. Its proteolytic properties enable it to
directly modify substrates such as cytokines in their natural
in vivo form, (e.g., CXCL12, CCL5, CXCL11, CXCL10,
GLP-1/2) [1, 4, 7, 14].
In human skin, DPPIV is known to be expressed on
keratinocytes and known to be upregulated in psoriasis [4,
13, 19, 22]. However, little data are available concerning
the potential functional implications of such an upregula-
tion. Selective blockers of DPPIV activity are currently
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[15]. Recently, it was shown that such an inhibition could
suppress keratinocyte proliferation in vitro and partially
restore keratinocyte diVerentiation in vivo [19]. Mapping
the DPPIV glycoprotein in psoriasis may therefore add to
our current knowledge. Considering the common grounds
of the three main pathological components of psoriasis (T
cells, keratinocytes and cytokines) and the various proper-
ties of DPPIV, it is attractive to speculate that DPPIV might
be involved in the modulation of the inXammatory process
and the keratinocyte abnormalities in psoriasis.
Ensued from this, our goal was to map the epidermal
expression and enzyme activity of DPPIV in relation to
known markers of proliferation (Ki-67) and abnormal mat-
uration (Keratin 16) of psoriatic keratinocytes in the epider-
mis [10]. Coherence in dynamics of expression of these
three markers could result in expanding knowledge on the
existing epidermal disbalance in psoriasis. We studied the
expression and enzyme activity of DPPIV in the dynamic
margin zone of the psoriatic lesion in order to investigate
whether DPPIV distribution diVers with the distribution of
K16 and Ki-67 in clinically uninvolved psoriatic skin, in
the early lesion and subsequently in the chronic psoriatic
lesion. Accordingly, coherence in dynamics of DPPIV
(expression and enzyme activity) with keratinocyte prolif-
eration and diVerentiation markers during the development
of a psoriatic plaque could reveal more insight into the




A total of seven psoriatic patients (mean age § SEM,
63 § 3 years) with mild-to-moderate plaque psoriasis [Pso-
riasis Area and Severity Index (PASI) ¸2 and ·12] and a
control group, composed of three healthy volunteers (mean
age 52 § 6 years), participated in this study. Patients had
stable plaque-type psoriasis. None of the participants had
used any systemic anti-psoriatic or immune-modulating
therapy for at least 4 weeks and no topical therapy for at
least 2 weeks prior to the biopsy. The healthy volunteers
had no history of dermatological or immunological disease.
All participants had given written informed consent before
enrollment.
Biopsies
From the psoriatic patients three 4-mm punch biopsies were
obtained, respectively, from the centre of the plaque, the
inner margin of the plaque comprising the outmost clini-
cally involved area and the clinically uninvolved skin (at
least 2 cm from the lesion). From the healthy volunteers
one 4-mm punch biopsy was obtained. All participants
received local anesthesia (1% xylocaine/adrenaline) before
the biopsies were taken. Skin defects were optionally
closed with one suture. The obtained specimens were
embedded in Tissue-Tek OCT compound (Sakura, Zoeter-
woude, Netherlands), snap-frozen in liquid nitrogen and
stored at ¡80°C until use.
Histochemical methods
Immunohistochemical procedure
The immunohistochemical staining was performed as
described previously [2, 23]. BrieXy, cryostat sections of
7 m were sliced onto (3-amino propyl)triethoxysilane
(AAS)-coated slides, air-dried for 10 min and Wxed in cold
acetone for 10 min. After blocking for endogenous peroxi-
dase for 20 min, sections were incubated with either CD26
monoclonal antibody (1:50) (clone BA-5, Santa Cruz Bio-
technology, Santa Cruz, FL), Ki-67 (1:25) (clone MIB-1,
DAKO, Copenhagen, Denmark) or anti-Keratin-16 (1:20)
(clone LL025, Monosan, Uden, Netherlands), diluted in
1%BSA/PBS for 1 h. Subsequently, sections underwent
secondary incubation with IgG-labelled polymer, horserad-
ish peroxidase antimouse-antibody EnVision+ (DAKO,
Copenhagen, Denmark) for 30 min. As a coloring agent
aminoethylcarbazole + high-sensitivity substrate chromo-
gen (DAKO, Copenhagen, Denmark) was used for 10 min
at 37°C. Before and after each incubation, sections were
washed with PBS for 15 min. All incubations were per-
formed in a dark, humid environment. Counterstaining was
performed with Mayer’s hematoxylin. Subsequently, the
sections were mounted in glycerol gelatin.
Enzymehistochemical procedure
The demonstration of DPPIV activity was achieved using
the method, described by Khalaf et al. [9] with some minor
modiWcations [22]. The frozen biopsies were sliced into 10-
m sections on AAS-coated slides. These were air-dried for
20 min and Wxed in cold acetone for 10 min. For the incu-
bation mixture, 3 mg of glycyl-propyl-4-methoxy-2-naph-
thylamide (GPMN) (Bachem, Bubendorf, Switzerland) was
dissolved in 0.2 ml dimethylformamide. This substrate was
added to 4.6 ml of PBS and subsequently mixed with 5 mg
of fast blue B salt (FBB) (Sigma–Alderich, St. Louis, MO)
dissolved in 0.2 ml dimethylformamide and Wltered. The
samples were incubated in a humid, dark chamber at room
temperature for 45 min with 200 l of the incubation mix-
ture added to each section. After incubation the slides were
washed with distilled water, brieXy counterstained with123
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water. After rinsing with distilled water, they were mounted
in glycerol gelatin.
Negative and positive controls
In the immunohistochemical procedure, as a negative con-
trol the primary antibody was omitted. As a negative con-
trol in the enzymehistochemical procedure, inhibition of
DPPIV activity was accomplished by pretreating the slides
with 200 l of 5 mM Diprotin A (Peptides International,
Louisville, KY) for 15 min at 37°C [3]. As positive control,




The immunohistochemical and enzymehistochemical
DPPIV-stained sections were analyzed using transmission
light microscopy with an objective magniWcation of 200£.
Per patient, three of the diVerent biopsy sections (center,
inner margin, clinically uninvolved psoriatic skin) were
analyzed for the full width of the section. For quantiWcation
of the epidermal DPPIV expression and enzyme activity,
the following semi-quantitative Wve-point scale was used:
0 = no staining, 1 = slight staining, 2 = moderate staining,
3 = moderately pronounced staining, 4 = pronounced stain-
ing.
In order to analyze K16 and Ki-67 positive cells, digital
photographs were made at 100£ magniWcation. Each pho-
tograph was analyzed using IP-lab software (Scanalytics,
USA). For quantiWcation of the number of cells positive for
Ki-67 and the percentage epidermal area positive for K16, a
deWned window was set in the epidermis as the region of
interest (ROI) which was representative for the whole sec-
tion. The total ROI and the K16-positive area within the
ROI were measured. The K16 value was expressed as per-
centage K16-positive area of the ROI (%). The number of
Ki-67 positive cells was determined by counting the Ki-67
positive nuclei in a representative epidermal ROI. A line,
following the stratum basale of the ROI, was set out and
measured. The number of Ki-67 positive nuclei was
expressed as positive cells per mm length of basement
membrane.
Statistical analysis
Results are presented as means §SD of the mean. All anal-
yses were carried out using Statistica® statistical software,
version 7.0. Comparison of the non-parametric immunohis-
tochemical and enzymehistochemical DPPIV values for the
plaque centre, inner margin and clinically uninvolved skin
was performed using the Kruskal–Wallis analysis of vari-
ance. For analysis of the markers K16 and Ki-67 concern-
ing the plaque centre, inner margin and clinically
uninvolved skin we performed analysis of variance
(ANOVA) and if signiWcant, Duncan’s post hoc compari-
son was performed. The Student’s t test was carried out to
study the diVerence in expression of markers between the
uninvolved psoriatic skin and the healthy volunteers skin.
Correlation was tested with the Spearman’s correlation test.
Statistical signiWcance was set at P < 0.05.
Results
Patients
Histologically, the skin of the healthy volunteers was nor-
mal (hematoxylin–eosin staining). Seven patients (5 males,
2 females) diagnosed with psoriasis participated. In order to
assess the severity of the psoriatic lesion used for biopsy,
SUM scores (0–12) were determined. SUM score is a psori-
atic lesion severity score, comprising erythema (0–4), indu-
ration (0–4) and desquamation (0–4) wherein a score of 0
represents no psoriasis and 12 the highest possible severity
of the plaque. The mean SUM score in this study was
5.57 § 0.34.
Epidermal distribution of dipeptidyl-peptidase IV, Ki-67 
and Keratin-16 (Fig. 1)
In correspondence with earlier Wndings [22], upregulation
of DPPIV on keratinocytes was seen in all of the patients,
although to a diVerent extent. In line with these earlier Wnd-
ings, the immunohistochemical and the enzymehistochemi-
cal staining of DPPIV followed a similar epidermal pattern;
focally pronounced patches of staining, mainly displaying a
honeycomb like structure, in psoriatic sections. In those of
the healthy volunteers this pattern was practically absent. In
brief, the psoriatic pattern was generally more extensive
and predominantly located para-papillary with an optimum
in the epidermal area around the top of the papillae. Usually
the staining was conWned to the lower two third of the total
epidermis, or more speciWcally to the lower three quarters
of the stratum spinosum (Fig. 1). In both healthy and psori-
atic skin, no staining in the stratum lucidum was observed.
In the psoriatic coupes, additional column-like structures
could regularly be observed.
The DPPIV immunohistochemical expression and
enzyme activity in the centre of the plaque, the inner mar-
gin and the clinically uninvolved skin showed a comparable
pattern with correlations, respectively, of 0.79, 0.85 and
0.87 (P<0.02). Considering this comparable pattern, the123
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erence for drawing comparisons with the Ki-67 and K16
markers as it encompasses more potential to study dynam-
ics than the protein expression does. Namely, protein
expression only conWrms the presence of DPPIV whereas
enzyme activity denotes presence and activity of DPPIV.
As far as the proliferation marker Ki-67 is concerned, it
predominantly appeared in the stratum basale in both psori-
atic and healthy skin although to a diVerent extent (Fig. 1).
Solitary Ki-67 positive cells could be observed sporadically
in the stratum spinosum of the clinically uninvolved skin of
psoriatics and the skin of healthy volunteers. Obviously, in
the centre and inner margin of the psoriatic lesion, gener-
ally a greater number of Ki-67-positive cells was observed
in all patients.
Keratin-16, a diVerentiation marker, only stained posi-
tive in the epidermis of the plaque centre and inner margin
conWrming the aberrant diVerentiation in these parts as
opposed to the clinically uninvolved psoriatic and healthy
skin (Fig. 1). The staining was seen throughout the whole
stratum spinosum, with an optimum towards the stratum
basale.
Dynamics in epidermal distribution of dipeptidyl-peptidase 
IV, Ki-67 and Keratin-16 (Fig. 2)
Throughout the dynamics of the margin zone of the psoriatic
lesion, a stronger signiWcant DPPIV enzymatic activity could
be noticed in both the inner margin and centre of the lesion
compared to the clinically uninvolved psoriatic skin
(1.38 § 0.24 and 1.57 § 0.27 vs. 0.62 § 0.15; P < 0.01 and
P < 0.05) (Fig. 2). Clinically uninvolved psoriatic skin also
showed a signiWcant increase in enzymatic activity compared
to skin of healthy volunteers (P < 0.05). However, when
observing the expression in the centre and the inner margin
mutually, no signiWcant diVerence in expression was detected.
Equal to the DPPIV enzyme activity, Ki-67 antigen was
signiWcantly strongly expressed in both the plaque centre
Fig. 1 Expression of DPPIV 
protein expression, enzyme 
activity, Keratin 16 and Ki-67 
throughout the margin zone of a 
psoriatic lesion compared to nor-
mal skin. Plaque centre, inner 
margin, clinically uninvolved 
skin (UIS): £200 magniWcation. 
Healthy volunteers skin (HV): 
£100 magniWcation. Notice-
ably, in the skin of healthy vol-
unteers the DPPIV enzyme-
activity staining creates a 
brownish background staining
Fig. 2 Mean scores of DPPIV 
enzyme activity, Ki67 and K16 
expression throughout the mar-
gin zone. * = signiWcant. 
(Mean § SEM)123
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psoriatic skin (172.65 § 16.06 and 167.60 § 13.84 vs.
70.44 § 7.97; both P < 0.01) (Fig. 2). The clinically unin-
volved psoriatic skin showed a stronger proliferation ten-
dency of keratinocytes than the healthy volunteers skin,
albeit borderline signiWcant (P = 0.057). However, when
observing the Ki-67 expression in the centre and the inner
margin mutually again, no signiWcant diVerence in expres-
sion was detected.
With respect to the expression of K16 in the various
parts of the margin zone, the plaque centre and the inner
margin showed signiWcantly more expression of K16 in
comparison to the clinically uninvolved psoriatic skin
(67.0 § 3.13 and 65.43 § 2.1 vs. 0 § 0) (Fig. 2). This was
in line with the expected expression pattern because in
uninvolved psoriatic skin and healthy volunteers skin there
exists a natural absence of K16 expression. Mutually how-
ever, the centre and margin did, once more, not diVer sig-
niWcantly in K16 expression.
Correlation of epidermal distribution of dipeptidyl-peptidase 
IV, Ki-67antigen and K16
In general, there were no signiWcant correlations observed
between enzymatic cytochemical activity of DPPIV and
expression of aberrant proliferation or diVerentiation of
keratinocytes throughout the dynamics of the margin zone.
Remarkably, the Ki-67 positive cell count and percent-
age of K16 positively stained epidermis showed a strong
overall correlation in the psoriatic patients, taking together
both the plaque centre and the inner margin ( = 0.88;
P < 0.05). Though, when investigating the correlation of
these markers per locus separately, no signiWcant correla-
tion could be observed (plaque centre  = 0.54; inner mar-
gin  = 0.3).
Discussion
Dipeptidyl peptidase IV has diverse properties as an ecto-
peptidase, enabling it to play a key role in the chronic pso-
riatic immune response which is mainly orchestrated by T
cells, cytokines and keratinocytes in psoriasis. Direct evi-
dence that DPPIV inhibitors are relevant to keratinocyte
biology has been provided by the observation that such
inhibitors can suppress keratinocyte proliferation in vitro
and can partially restore keratinocyte diVerentiation in
vivo [19]. This would imply that DPPIV may aVect and
interact with the aberrant keratinocyte abnormalities in
psoriasis. In line with previous Wndings [22], the present
study conWrms a strong upregulation of DPPIV on kerati-
nocytes in psoriatic epidermis but additionally reveals it
to be continuously present throughout the dynamics of the
margin zone. Moreover, it aimed to shed light on the func-
tional implication of this upregulation combining it with
the expression of markers characteristic for proliferation
(Ki-67) and diVerentiation (K16) in psoriatic keratino-
cytes as coherence in dynamics of expression of these
markers could result in creating an epidermal biomarker
in psoriasis.
Topographically, the distribution of the enzyme activity
of DPPIV did not coincide entirely with the areas of hyper-
proliferation and aberrant diVerentiation of keratinocytes in
a psoriatic section which ultimately makes DPPIV expres-
sion (enzyme activity and protein expression) an entity in
itself in psoriasis. The margin zone was previously proven
to be a suitable model for studying the dynamics of a psori-
atic lesion by representing the chronic and the early process
and the uninvolved skin [6, 20, 23]. The inner margin was
presumed to represent an early active lesion and therefore
reXecting a diVerent level of expression. DPPIV enzyme
activity, Ki-67 and K16, all three show, throughout the
margin zone, signiWcant upregulation in the centre and
inner margin of the plaque compared to the clinically unin-
volved skin and the healthy volunteers skin. However,
mutually the upregulation in expression in the centre and
inner margin did not diVer signiWcantly for both the Ki-67,
K16 marker as well as for DPPIV enzyme activity. One
could suggest that in this study within a psoriatic lesion
there exists a homogeneous level of keratinocyte prolifera-
tion, diVerentiation and DPPIV enzyme activity as parts
representing an early (inner margin) or more chronic (cen-
ter) lesion do not seem to make a diVerence in expression
for the markers under study. Moreover, correlation tests
applied to the margin zone in this investigation showed no
coherence in dynamics of epidermal DPPIV enzyme activ-
ity, hyperproliferation and aberrant diVerentiation of kerati-
nocytes.
The symptomless skin at 2-cm distance from a psoriatic
lesion proved to have signiWcantly elevated DPPIV enzyme
activity as compared to skin of healthy volunteers, whereas
Ki-67 and K16 were essentially slightly present or absent in
the symptomless skin. Although the symptomless skin may
harbor some “preclinical lesions” or can be subclinically
involved, we can conclude that in an early phase of the pso-
riatic process well before an overt lesion has developed, an
increased DPPIV enzyme activity is present clearly show-
ing that DPPIV is involved in an early phase of the psoriatic
cascade [8, 12].
A number of other molecules exhibiting DPPIV-like
enzyme activity have been introduced recently, and termed
“DPP-IV activity and/or structure-homologues” (DASH)
[17]. This group comprises several proteases including attr-
actin, DPP 8 and 9 [16, 17]. DASH have potential abilities
to complement and/or functionally substitute DPPIV on the
level of its enzymatic activity. In this light, a marginal note123
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like processes (as could be the case in the current investiga-
tion). Due to the ubiquitous expression pattern and multi-
functional nature of DPPIV speciWcally and the majority of
the DASH in general, it may be diYcult to deduce the
selectivity of DPPIV from the DASH group. However, our
results did not show discrepancies between the immunohis-
tochemical and enzymehistochemical staining, which
implies that the possible presence of DPPIV homologues
does not interfere with the interpretation of the data in the
current study.
Our goal was to determine whether the distribution of
DPPIV in the epidermis throughout the dynamics of the
margin zone, coheres with markers for proliferation and
diVerentiation of keratinocytes in psoriasis in order to
expand knowledge on the existing epidermal dysbalance in
psoriasis. Considering the localization of DPPIV expres-
sion and enzyme activity in the epidermis, being primarily
concentrated towards the (supra) basal layers, it is possible
to presume an active role for DPPIV in the proliferation of
keratinocytes in the pathogenesis of psoriasis. On the other
hand, considering the functional enzymatic characteristics
of DPPIV, it may well be feasible that the peptidase activity
actually restrains the inXammatory disbalance in the psori-
atic skin through down-regulation of cytokines secondarily
aVecting the keratinocyte malfunctioning. Therefore, the
psoriatic skin represents an interesting eVector organ for
DPPIV inhibitors which could tackle not only keratinocytes
and cytokines but also (DPPIV+) T cells, key players in the
psoriatic pathogenesis all sharing common grounds with
DPPIV. Future studies should address the eVect of such
inhibitors in psoriasis.
In conclusion, we have demonstrated diVerential expres-
sion and activity of DPPIV in normal and diseased skin
throughout the dynamics of the margin zone. In addition,
we have shown that DPPIV (protein expression and
enzyme activity) is expressed well before the development
of the overt psoriatic lesion before the accumulation of T
cells and other inXammatory cells. Moreover, the DPPIV
enzyme activity does not increase signiWcantly in the more
chronic phase of the psoriatic process. Therefore, DPPIV is
a consistent feature of the psoriatic lesion. The abnormal
enzyme activity in psoriatic diseased skin does not seem to
correlate with known markers of aberrant growth and
diVerentiation of keratinocytes, which makes DPPIV a
marker standing on its own. Future studies should focus on
whether DPPIV can be regarded a useful biomarker for
therapy evaluation.
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